Couldn't help but comment on this one.
In TheStreet.com's weekly 'Biotech Stock Mailbag' - for which a more fitting title might be 'Feuerstein's Ode To Himself' - the biotech blogger made a couple of comments that were too comical to ignore.
The first came while commenting on Neoprobe (NEOP) and that company's recently released positive trial results. In his commentary, the biotech blogger advised his readers that when looking at a stock and a company to invest in, that one must look at both the long and short side of the story before making a determination. That bit of advice fit right into his commentary about Neoprobe, since he was out searching for the short side of what has been a great ride for investors of late.
I'll admit, I agree with the guy on having to look at both the bullish and bearish sides of the potential of a company, but the problem is - those words are a joke coming from this guy.
Take a look at his blogging about CVM and RPC, for recent examples, and just about every other stock that he writes about (including the pre-approval DNDN - which he got wrong), and you'll see that you're only getting the short side of the story with no consideration for the potential bullish side.
BS? Coming from this guy, it's a load of it. The old saying goes, "Practice what you preach," but he actually gets a pass with this one, because he rarely preaches that there is an upside to investing in biotech. As bad and criminal as he makes this sector out to be, one's got to wonder why he decided to make a living writing about it.
Couldn't let that comment slip by, because coming from him it was pretty funny. I think he meant it tongue-in-cheek, actually, since his readers know that he's all about the short side of everything.
Another comment he made this week that got a chuckle out of VFC was when he gave himself a big old pat on the back for receiving an extra hefty amount of hate mail. Ya gotta love it when in a place like America, a guy judges his success on how many people don't like him.
On top of that, in the same breath he pats himself on the back again for TheStreet.com being at the top of the game, but that's the same TheStreet.com that's been getting beat in the Internet "ratings" by Seeking Alpha these days.
Then again, for them it's all about hate mail, controversy and the short side of the story (what TheStreet.com and the biotech blogger consider to be "journalism"), and little else - unless you want to include page views into that comment.
Anyway, just thought the couple of lines of BS were worth noting.
Enjoy the weekend.
